Mesa Labs Q1 revenue up 2.4%, operating income down 45%
Overview
Mesa Labs fiscal Q1 revenue grows 2.4% yr/yr, driven by strong SDC growth
Operating income declines 45.1% due to FX impacts and stock-based compensation
Co expects improved AOI as percentage of revenues in fiscal Q2
Outlook
Company expects 2Q26 revenue boost from delayed BPD orders
Mesa sees AOI percentage improving in 2Q26
Company aims to reduce past-due backlog in FY26
Mesa expects BPD gross profit to improve as mix normalizes
Result Drivers
SDC GROWTH - Sterilization and Disinfection Control division saw 7.5% core organic revenue growth, driven by strong commercial execution and reduced backlog
BPD DELAYS - Biopharmaceutical Development division faced a 7.0% decline in core organic revenues due to order timing delays and shipping issues
CG CHINA CONTRACTION - Clinical Genomics division experienced a 69% revenue contraction in China, attributed to macroeconomic and regulatory challenges
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 EPS |
| $0.85 |
|
Q1 Net Income |
| $4.74 mln |
|
Q1 Basic EPS |
| $0.87 |
|
Q1 Gross Profit |
| $36.94 mln |
|
Q1 Operating Expenses |
| $33.88 mln |
|
Q1 Operating Income |
| $3.06 mln |
|
Press Release: ID:nGNX2DJpmN
